tralesinidase alfa ("TA-ERT") — NDA/BLA submission
Q4 2026
Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026Source filing
SPRB biotech catalysts & pipeline
SPRUCE BIOSCIENCES INC · Data as of 2026-10-25